
Presenter(s): Daniel G. Tobin, MD, FACP
Target Audience: This activity is designed for physicians, advanced practice professionals, nurses, psychologists, pharmacists, social workers, residents/fellows, health professional students, and other mental health clinicians. This activity is accredited for physicians, nurses, PAs, pharmacists, interprofessional teams, and other health professionals.
Credit Designations Available: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Webinar Description: This activity focuses on the assessment, mitigation and management of risk when prescribing opioids for analgesia. Learners are introduced to the concept of universal precautions and their role in opioid therapy, as well as to practical monitoring and documentation strategies. The fundamental principles of urine drug testing and interpretation are also reviewed, as is the differential diagnosis of opioid misuse. Special attention is given to overdose prevention, naloxone co-prescribing, and how to recognize and respond to an emerging opioid use disorder when prescribing chronic opioid therapy for pain.
Educational Objectives:
- Describe the potential risks and benefits of opioid therapy in the treatment of acute and chronic pain
- Define “universal precautions” and their role in safe opioid prescribing
- Review safety monitoring and risk reduction strategies when prescribing opioids
- Explain the fundamental principles of urine drug testing and interpretation
- Assess the differential diagnosis for drug misuse and respond to newly identified opioid use disorder